Seritinib/ceritinib resistance management

Ceritinib/Ceritinib is a targeted drug commonly used to treat certain types of lung cancer. However, over time, some patients may develop resistance to ceritinib/ceritinib, resulting in reduced or ineffective drug efficacy. Doctors will conduct a comprehensive evaluation of the patient, including examining the patient's leukemia cells to understand the cause of drug resistance. This helps determine next steps in treatment. Doctors may try to combine ceritinib with different drugs to increase the effectiveness of treatment and delay the development of resistance. Such combination therapies may include other targeted drugs or chemotherapy drugs. Occasionally, adjusting the dose of ceritinib may be effective in some patients because resistance may be related to drug concentration.